Table 2 Clinical factors and its association with LTFU
From: Predictors of loss to follow-up in art experienced patients in Nigeria: a 13 year review (2004–2017)
Maternal factors | LTFU | Total | p (< 0.05) | |
|---|---|---|---|---|
No | Yes | |||
Regimen line at ART start | ||||
Adult 1st line | 140,977 (66.59) | 70,719 (33.41) | 211,696 (93.99) | 0.003 |
Adult 2nd line | 1530 (67.08) | 751 (32.92) | 2281 (1.01) | |
Peadiatrics 1st line | 7556 (68.24) | 3516 (31.76) | 11,071 (4.92) | |
Peadiatrics 2nd line | 128 (69.95) | 55 (30.05) | 183 (0.08) | |
Regimen line at end-point of study | ||||
Adult 1st line | 137,362 (66.26) | 69,937 (33.74) | 207,299 (92.04) | < 0.001 |
Adult 2nd line | 6310 (73.75) | 2246 (26.25) | 8556 (3.80) | |
Adult 3rd line/others | 8 (80.00) | 2 (20.00) | 10 (0.00) | |
Peadiatrics 1st Line | 6265 (69.33) | 2771 (30.67) | 9036 (4.01) | |
Peadiatrics 2nd Line | 246 (74.32) | 85 (25.68) | 331 (0.15) | |
Months of ARV refill | ||||
1 | 26,314 (50.63) | 25,662 (49.37) | 51,976 (23.08) | < 0.001 |
2 | 107,845 (73.53) | 38,815 (26.47) | 146,660 (65.12) | |
≥ 3 | 16,032 (60.28) | 10,554 (14.08) | 26,596 (11.81) | |
Duration on ART (month) | ||||
≤ 6 | 22,697 (40.57) | 33,249 (59.43) | 55,946 (24.84) | < 0.001 |
7–12 month | 14,465 (67.08) | 7098 (32.92) | 21,563 (9.57) | |
13–24 | 21,199 (69.20) | 9434 (30.80) | 30,633 (13.60) | |
25+ | 91,823 (78.43) | 25,258 (21.57) | 117,081 (51.98) | |
Current viral load (c/ml) | ||||
Undetected | 41,251 (92.65) | 3271 (7.36) | 44,552 (19.77) | < 0.001 |
Detected | 10,177 (82.55) | 2152 (17.45) | 12,329 (5.47) | |
None | 98,763 (58.65) | 69,618 (41.35) | 168,381 (74.76) | |
Current viral load (c/ml) | ||||
Suppressed | 27,751 (96.44) | 1025 (3.56) | 28,776 (12.78) | < 0.001 |
Unsuppressed | 23,677 (84.33) | 4398 (15.67) | 28,075 (12.46) | |
None | 98,763 (58.65) | 69,618 (41.35) | 168,381 (74.76) | |